Director Transactions

Insider Trades: Directors are buying shares in these 9 ASX 200 companies

Wed 22 Mar 23, 1:39pm (AEST)
REIT 24 office CBD towers
Source: iStock

Key Points

  • Harvey Norman CEO co-founder Gerry Harvey has purchased $50m worth of shares in March alone
  • Telix shares have held up relatively well amid recent market volatility
  • Aurizon shares are trying to bottom after a post earnings slump

A summary of noteworthy S&P/ASX 200 director transactions between 14-21 March.

Top large cap insider buys

Code

Company

Date

Director

Type

Price

Value

Notes

HVN

Harvey Norman

15/3/23

Gerald Harvey

Buy

$3.82

$11,837,970

On-market trade

HVN

Harvey Norman

14/3/23

Gerald Harvey

Buy

$3.79

$6,015,167

On-market trade

TLX

TELIX Pharmaceuticals

16/3/23

Tiffany Olson

Buy

$6.69

$343,385

On-market trade

AZJ

Aurizon

14/3/23

Timothy Poole

Buy

$3.26

$228,100

On-market trade

AKE

Allkem

15/3/23

Fernando de Roa

Buy

$10.64

$212,705

On-market trade

DOW

Downer Edi

15/3/23

Mark Menhinnitt

Buy

$3.25

$162,260

On-market trade

GMG

Goodman Group

15/3/23

Hilary Spann

Buy

$19.31

$102,343

On-market trade

AGL

AGL Energy

17/3/23

Kerry Schott

Buy

$6.90

$100,050

On-market trade

DDR

Dicker Data

14/3/23

Vladimir Mitnovetski

Buy

$8.23

$58,336

On-market trade

CNU

Chorus

14/3/23

Sue Bailey

Buy

$7.70

$38,520

On-market trade

Interesting observations

Harvey Norman: Mr Harvey loads up more

A week ago, we noted how "in March alone, co-founder and executive chairman, Gerry Harvey purchased six parcels worth a collective $20.7 million."

Since then, he's added four more parcels worth $29.2 million.

In the grand scheme of things, the ten parcels have grown his existing stake by about 3.4% to 393 million shares or 31.6% of the company.

Telix Pharma: Moving sideways

Telix shares have held up relatively well amid recent market volatility, up 8.2% in the past week and up 44.7% in the past twelve months.

Non-executive director Tiffany Olson has been the only director to have made purchases in the last 11 months. The three purchases include:

  • 16 Mar 23: $343,385 at $6.69 per share

  • 12 Dec 22: $73,255 at $6.70 per share

  • 3 Jun 22: $135,665 at $4.11 per share

Interestingly, Bell Potter has a BUY rating for the stock with a $9.00 target price.

"In our view the label expansion (for Illuccix prostate cancer imaging agent) is priced in, i.e. no further increases to revenue forecasts at this time. The next major catalysts for the stock includes the March quarter cash where we expect the company to deliver its first quarter of positive cash from operations."

TLX chart
Telix Pharma 12-month price chart (Source: Market Index)

Aurizon: Stabilising after post earnings slump

Aurizon shares slumped on half-year earnings, down 11.65% between 13-15 February. The result materially disappointed with underlying EBITDA and net profit missed consensus expectations by 11.4% and 33.2% respectively.

The result was weighed by adverse weather impacts as well as softer coal volumes, which analysts expect to stabilise over the medium term.

Post earnings, the average target price among 14 major brokers was cut by 5.5% to $3.73.

Aurizon is starting to bottom around the $3.25 level and trying to push above its recent trading range.

AZJ chart
Aurizon 12-month price chart (Source: Market Index)

 

Related Tags

Written By

Kerry Sun

Content Strategist

Kerry holds a Bachelor of Commerce from Monash University. He is an avid swing trader, focused on technical set ups and breakouts. Outside of writing and trading, Kerry is a big UFC fan, loves poker and training Muay Thai. Connect via LinkedIn or email.

Get the latest news and insights direct to your inbox

Subscribe free